NasdaqGS - Delayed Quote • USD
Erasca, Inc. (ERAS)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:37 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
141,525.0000
141,525.0000
145,450.0000
96,538.0000
37,507.0000
Operating Income
-141,525.0000
-141,525.0000
-145,450.0000
-96,538.0000
-37,507.0000
Net Non Operating Interest Income Expense
16,712.0000
16,712.0000
4,902.0000
190.0000
336.0000
Other Income Expense
-229.0000
-229.0000
-102,257.0000
-26,416.0000
-64,489.0000
Pretax Income
-125,042.0000
-125,042.0000
-242,805.0000
-122,764.0000
-101,660.0000
Net Income Common Stockholders
-125,042.0000
-125,042.0000
-242,805.0000
-122,764.0000
-101,660.0000
Diluted NI Available to Com Stockholders
-125,042.0000
-125,042.0000
-242,805.0000
-122,764.0000
-101,660.0000
Basic EPS
-0.83
--
-1.99
-1.85
-4.44
Diluted EPS
-0.83
--
-1.99
-1.85
-4.44
Basic Average Shares
150,184.9940
--
122,024.8480
66,290.5920
22,893.5330
Diluted Average Shares
150,184.9940
--
122,024.8480
66,290.5920
22,893.5330
Total Operating Income as Reported
-141,525.0000
-141,525.0000
-247,450.0000
-124,883.0000
-109,252.0000
Total Expenses
141,525.0000
141,525.0000
145,450.0000
96,538.0000
37,507.0000
Net Income from Continuing & Discontinued Operation
-125,042.0000
-125,042.0000
-242,805.0000
-122,764.0000
-101,660.0000
Normalized Income
-125,042.0000
-125,042.0000
-140,805.0000
-94,419.0000
-29,915.0000
Interest Income
16,712.0000
16,712.0000
4,902.0000
190.0000
336.0000
Net Interest Income
16,712.0000
16,712.0000
4,902.0000
190.0000
336.0000
EBIT
-141,525.0000
-141,525.0000
-145,450.0000
-96,538.0000
-37,507.0000
EBITDA
-137,793.0000
-137,793.0000
-142,809.0000
-95,709.0000
-36,967.0000
Reconciled Depreciation
3,732.0000
3,732.0000
2,641.0000
829.0000
540.0000
Net Income from Continuing Operation Net Minority Interest
-125,042.0000
-125,042.0000
-242,805.0000
-122,764.0000
-101,660.0000
Total Unusual Items Excluding Goodwill
--
--
-102,000.0000
-28,345.0000
-71,745.0000
Total Unusual Items
--
--
-102,000.0000
-28,345.0000
-71,745.0000
Normalized EBITDA
-137,793.0000
-137,793.0000
-40,809.0000
-67,364.0000
34,778.0000
12/31/2020 - 7/16/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ORIC ORIC Pharmaceuticals, Inc.
8.07
+5.22%
ZNTL Zentalis Pharmaceuticals, Inc.
11.06
+0.68%
BOLD Boundless Bio, Inc.
11.64
-3.56%
GLUE Monte Rosa Therapeutics, Inc.
5.33
-2.20%
FULC Fulcrum Therapeutics, Inc.
7.14
+0.14%
IPSC Century Therapeutics, Inc.
2.8800
-8.57%
YMAB Y-mAbs Therapeutics, Inc.
14.71
-0.88%
RVMD Revolution Medicines, Inc.
35.96
+1.78%
ENVB Enveric Biosciences, Inc.
0.8950
-2.45%
ELYM Eliem Therapeutics, Inc.
3.9800
+17.40%